RAPT Therapeutics Announces Management Promotions
March 04 2020 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced the promotions of Paul
Kassner, Ph.D., to Senior Vice President of Quantitative and
Computational Biology and Lisa Moore, Ph.D., to Vice President of
Business Development and Strategy.
“Both Paul and Lisa continue to make incredible contributions to
RAPT’s success in setting and implementing strategic business and
scientific plans,” said Brian Wong, M.D., Ph.D., President and CEO
of RAPT Therapeutics. “Paul’s promotion recognizes his excellence
in driving data-driven analyses and execution of our preclinical
programs as well as the development of key clinical biomarker
assays that have informed and accelerated our two lead clinical
programs FLX475 and RPT193. Lisa led our efforts to secure a
strategic collaboration with Hanmi Pharmaceutical Co., LTD, for
FLX475 in Asia, excluding Japan and other territories, and
consistently builds and maintains strong relationships with our
alliance partners, including with Merck.”
Paul joined RAPT Therapeutics in 2016, as Vice President of
Quantitative and Computational Biology. He has more than 20 years
of experience building and leading high-performance technical
groups in various biopharmaceutical organizations. Most recently,
Paul was Director of Research and Head of the Genome Analysis Unit
at Amgen, Inc. During his eleven years at Amgen, he developed and
implemented multiple high-throughput platforms for drug discovery
and target identification across a broad spectrum of therapeutic
areas. Prior to Amgen, Paul held scientific and leadership
positions in several smaller companies, which enabled him to
exercise his passion for creating novel technology platforms to
enable drug discovery. Paul received his B.S. in Genetics and
Development from the University of Illinois at Champaign-Urbana
before performing graduate research at the Dana-Farber Cancer
Institute and earning his Ph.D. in Immunology from Harvard
University. Paul completed postdoctoral work in Cellular
Neuroscience at the University of California, San Diego.
Lisa joined RAPT Therapeutics in 2018, as Senior Director of
Business Development and Strategy. With more than 20 years of
experience in business and scientific leadership, at RAPT she is
responsible for lead asset partnering and out-licensing, having
secured a significant partnership with Hanmi Pharmaceutical Co.,
LTD. Prior to joining RAPT, she served as Director of Alliance
Management for Nurix, Inc. where she managed drug discovery and
development strategic alliances with pharma partners in addition to
management of strategic research collaborations. Previously, she
served as Associate Director of Alliance Management for Novartis
Diagnostics managing four commercial alliances as well as
establishing cross-functional operating committees to govern
product development and commercial activities. Prior to Novartis,
she held positions of escalating responsibility at Codexis, Incyte
and Exelixis. She received her Ph.D. in Biology from the
Massachusetts Institute of Technology and her B.A. in Biology from
the University of California, Santa Cruz.
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including general control nonderepressible 2 (GCN2) and
hematopoietic progenitor kinase 1 (HPK1), that are in the discovery
stage of development.
Forward-Looking Statements This press release
contains forward-looking statements. These statements relate to
future events and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or
achievements to be materially different from any future
performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. These risks and uncertainties include, but are not
limited to the outcome, cost, and timing of our clinical trials,
our ability to obtain funding for our operations, the accuracy of
our estimate of the number of people affected by atopic dermatitis,
and other risks. Detailed information regarding factors that may
cause actual results to differ materially from the results
expressed or implied by statements in this press release may be
found in the section entitled “Risk Factors” in RAPT’s registration
statement on Form S-1 filed with the Securities and Exchange
Commission on February 4, 2020 and subsequent filings made with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. RAPT disclaims any
obligation to update these forward-looking statements.
Media Contact: Angela Bitting media@rapt.com (925) 202-6211
Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024